drugset / Trial / NCT04246905

A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression

NCT04246905

Phase 2 Unknown 90 enrolled Central South University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Major depressive disorder is a serious, recurrent and disabling mental disorder, which is the second leading cause of years lost to disability worldwide. Accumulating evidence suggests the important role for inflammation and oxidative stress in the pathophysiology of depression. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested sulforaphane activates Keap1-Nrf2 system to prevent depression-like phenotype in mice. In this study, the investigator attempts to evaluate the efficacy, safety, and tolerability of sulforaphane plus a fixed oral antipressant in adult participants diagnosed with depression.

Timeline

Start
2020-07-15
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sulforaphane Small molecule

Indications